Sweden’s Moberg completes financing

Funding round completed

Moberg Derma AB completed a financing of SEK 27.7 million (about €3 millionin a round led by the Baltic Sea Foundation (Östersjöstiftelsen) with other institutional and private investors, as well as members of management.

“The newly raised fund will allow us to start a phase III trial in September for K101, a novel topical treatment for onychomycosis (nail fungus),” said Peter Wolpert, CEO. “It will also help us to meet our goal of having two products in late-stage clinical development by the end of this year.”